Aurealis Therapeutics Proudly Sponsors EWMA Diabetic Foot Committee
Aurealis Therapeutics is pleased to announce our sponsorship of the newly established EWMA Diabetic Foot Committee, an initiative launched by the European Wound Management Association (EWMA) in 2023. This committee is dedicated to improving the management and care of diabetic foot ulcers (DFUs) across Europe by implementing an International Working Group on the Diabetic Foot […]
Interview with Laurent Décory COO at Aurealis Therapeutics | Career journey, AUP-16 advancements and global partnerships
At Aurealis Therapeutics, our mission is to revolutionize the treatment of chronic wounds, cancer, and inflammatory diseases with our multi-target cell and gene therapy platform. Central to this mission is our incredible team, whose dedication and expertise drive our progress forward. Through the Aurealis Therapeutics Team Interviews, we showcase the scientific advancements at our company […]
Aurealis Therapeutics Concludes Successful Partnering Week in China
Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, announced the successful completion of its partnering visit to China from 13-17 May, 2024. The week-long visit, led by CEO Juha Yrjänheikki and COO Laurent Decory, was aimed at strengthening partnerships and exploring potential investment opportunities in one of […]
Interview with Hanna-Riikka Kärkkäinen Head of Quality and Regulatory Affairs at Aurealis Therapeutics | Professional career, AUP-16 PRIME designation, FDA Advice & more
What was the journey that took Hanna-Riikka Kärkkäinen to her current role as Head of Quality and Regulatory Affairs? What does having the PRIME designation for AUP-16 mean? What was the result of the FDA Advice that Aurealis had with respect of AUP-16? How are the preparations to take AUP-16 to the world moving forward? […]
Interview with Haritha Samaranayake CMO of Aurealis Therapeutics | Professional journey, AUP-16 clinical trials in DFU & development plans for oncology
Watch full interview on YouTube What was the journey that took Haritha Samaranayake to his current role as CMO? What are the current advances in the clinical trials of Diabetic Foot Ulcers? How can the Aurealis technology be leveraged for cancer treatment? We discussed this and more in the interview with Haritha so let’s get […]
Aurealis Therapeutics presented advancements in multi-target bacterial gene therapies at the 14th International Symposium on Lactic Acid Bacteria
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, is making remarkable advances in the field with its 4-in-1 technology platform. Director of Genetic Engineering & Manufacturing, Igor Mierau, showcased the company’s research and results at the 14th International Symposium on Lactic Acid Bacteria, held […]
Aurealis Therapeutics shines in Nordic Life Science News with in-depth interview on gene therapy innovations
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, is excited to share its recent feature in the well-known life science journal, Nordic Life Science News. The article titled “From Theory to Therapy: Gene Therapy” has shared remarkable insights from an interview with Laurent Décory, COO […]
Aurealis Therapeutics accelerates oncology program: First abstract published at ASCO as the team prepares for Annual Meeting in Chicago
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, accelerates its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55. The company’s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has […]
Aurealis Therapeutics will be presenting during the European Wound Management Association (EWMA) 2023 Conference
Aurealis Therapeutics is excited to sponsor the European Wound Management Association (EWMA) 2023 Conference taking place in Milan, Italy from 3-5 May 2023. Our CEO Juha Yrjänheikki, COO Laurent Décory, and CMO Haritha Samaranayake and will be attending the conference. We will actively participate several parts of the event: On the 4th of May, Laurent Décory, COO […]
Aurealis Therapeutics is attending the Swiss Biotech Day 2023
Juha Yrjänheikki (CEO) and Laurent Décory (COO) will be attending the Swiss Biotech Day 2023 which will take place from 24-25 April in Basel, Switzerland. This will be a fantastic opportunity to meet investors and discuss potential partnerships with pharma companies. The Swiss Biotech Day is one of the leading biotechnology conferences in Europe offering […]
